Ocugen up after licensing deal for ophthalmic gene therapy in South Korea

Kwangdong Pharmaceutical

15/09/2025 11:57

** Shares of drug developer Ocugen OCGN.O up 9.4% at $1.17 premarket

** Co enters into a licensing agreement granting Kwangdong Pharmaceutical 009290.KS exclusive rights in South Korea to its experimental gene therapy, OCU400, for treating retinitis pigmentosa

** Retinitis pigmentosa, a genetic group of eye disorders, leads to progressive retinal degeneration and vision loss

** OCU400, currently in late-stage trials, is slated for a U.S. FDA application in 2026

** Under the agreement, Ocugen will receive up to $7.5 million in upfront licensing fees and near-term development milestones, with additional sales milestones of up to $180 million during the first decade of commercialization

** Ocugen will receive a royalty of 25% on net sales of OCU400 generated by Kwangdong

** As of last close, OCGN up 32.9% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))